Nutritional management of people living with cystic fibrosis throughout life and disease continuum: Changing times, new challenges
- PMID: 37515397
- DOI: 10.1111/jhn.13214
Nutritional management of people living with cystic fibrosis throughout life and disease continuum: Changing times, new challenges
Abstract
Cystic fibrosis (CF) is a genetic disease caused by mutations in the gene encoding for the ion channel cystic fibrosis transmembrane conductance regulator (CFTR). The management of CF disease has evolved in recent decades from treating downstream disease manifestations affecting the airways, the lungs and the gastrointestinal system to addressing the CFTR gene defect. The advent of CFTR modulators, which correct the functionality of the defective CFTR, contributes to reshaping the landscape of CF demographics, prognosis and therapies, including nutritional management. A spectrum of clinical manifestations is emerging within the same patient population where undernutrition and nutritional deficiencies coexist with excessive weight gain and metabolic derangements. Such contrasting presentations challenge current practices, require adjustments to traditional approaches, and involve more individualised interventions. This narrative review examines the current state of knowledge on the nutritional management of people living with cystic fibrosis from early life to adulthood in the era of CFTR modulation.
Keywords: CFTR modulators; cystic fibrosis; life stages; nutrition.
© 2023 The Authors. Journal of Human Nutrition and Dietetics published by John Wiley & Sons Ltd on behalf of British Dietetic Association.
References
REFERENCES
-
- Shteinberg M, Haq IJ, Polineni D, Davies JC. Cystic fibrosis. Lancet. 2021;397:2195-2211.
-
- Cystic Fibrosis Foundation. https://www.cff.org/managing-cf/cftr-modulator-therapies (2023). Accessed July 6 2023.
-
- Vertex Pharmaceuticals Incorporated. https://www.vrtx.com/medicines/our-approved-medicines/ (2023). Accessed July 6 2023.
-
- Graeber SY, Vitzthum C, Pallenberg ST, Naehrlich L, Stahl M, Rohrbach A, et al. Effects of elexacaftor/tezacaftor/ivacaftor therapy on cftr function in patients with cystic fibrosis and one or two F508del Alleles. Am J Respir Crit Care Med. 2022;205:540-549.
-
- Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry. Bethesda, Maryland: Cystic Fibrosis Foundation; 2022.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical